Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
about
The extrathyronine actions of iodine as antioxidant, apoptotic, and differentiation factor in various tissuesRegulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/IkappaB pathwayNucleobindin co-localizes and associates with cyclooxygenase (COX)-2 in human neutrophilsEffects of enriched environment on COX-2, leptin and eicosanoids in a mouse model of breast cancerPrognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysisNon steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and realityEvidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosisCOX-2 and cancer: a new approach to an old problemClinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor gamma in epithelial ovarian tumoursReduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control studyCombination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I studyInflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancermRNA profiling reveals determinants of trastuzumab efficiency in HER2-positive breast cancerUse of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) studyCyclooxygenase-2 and the inflammogenesis of breast cancer.Phylogenetic analysis of multiprobe fluorescence in situ hybridization data from tumor cell populations.Real-time changes in 1H and 31P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin.A systems approach to clinical oncology: focus on breast cancer.Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells.Expression of integrin α3β1 and cyclooxygenase-2 (COX2) are positively correlated in human breast cancer-765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia.Potentiation of neutrophil cyclooxygenase-2 by adenosine: an early anti-inflammatory signal.Algorithms to model single gene, single chromosome, and whole genome copy number changes jointly in tumor phylogenetics.Suppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells.Effect of cycloxygenase-2 silencing on the malignant biological behavior of MCF-7 breast cancer cells.Selective cyclo-oxygenase-2 inhibitors impair adipocyte differentiation through inhibition of the clonal expansion phase.Angiotensin II activates the calcineurin/NFAT signaling pathway and induces cyclooxygenase-2 expression in rat endometrial stromal cells.Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.Celecoxib: a specific COX-2 inhibitor with anticancer properties.Current concepts in cyclooxygenase inhibition in breast cancer.Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention.Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells.Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2.Endocrine-responsive breast cancer and strategies for combating resistance.Inhibition of apoptosis in normal and transformed intestinal epithelial cells by cAMP through induction of inhibitor of apoptosis protein (IAP)-2Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma.Cardiovascular effects of Phaleria macrocarpa extracts combined with mainstay FAC regimen for breast cancer.Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanismsChemotherapeutic potential of diazeniumdiolate-based aspirin prodrugs in breast cancer.
P2860
Q24630154-419681C2-5B42-40FC-91F7-08289EF500D0Q24806402-D22CB51A-CE8E-4A0C-A1B1-A91346B0A637Q27301317-98D1181A-825B-4BAD-87C0-E0A2FCB814B7Q27330395-E4C8D44B-ACD3-4B3F-8D49-82D8099A6E2EQ28067391-305A061B-5D51-466C-8E54-191C1B957041Q28166312-141C755C-870B-4D52-8A8E-473BB832B2B0Q28168893-BC0EB376-7993-4EC9-A578-45B58432F350Q28191533-ECD2FFC3-0B57-4266-A603-8CC287B9D7CEQ28209267-5FE6B872-ABA2-4BB9-946B-12F78AE24A9CQ28217572-EE7114B6-7609-477A-A9D1-2FB02880C9A3Q28218423-261FD006-CFD4-4FB4-B5FB-BDDE1B55C1E7Q28218639-15009169-37B8-4892-A9A8-EA5109F7A7F3Q28543647-2BB55DCD-F88F-4966-BC1D-0C675D993756Q28597617-12AFB2C0-81A1-4C40-95F4-62516FCDCD97Q30367680-AAE8702B-3CAC-40CA-ABC3-AE1B5F4AA534Q30652392-875A9CDE-4D4A-4102-8F3C-8EFC21BED718Q30744878-E435D128-E500-425F-BED6-EA8474A5D7D3Q33238889-A1C6530B-53BC-4D78-8CE6-D1F50AAC0B8EQ33260568-0AE38BDC-E6A1-449B-B93F-75A8F20E37A6Q33801546-746F4CE7-EDA9-4B35-97C7-94476BE6F648Q33869492-D0788816-CDC5-4FC2-B103-1EC3B087BFAAQ33940441-B1F84BE7-F2AC-4615-A6EA-BA269E33A4F3Q33981594-C42C89F1-B2E2-4AD3-947F-9C18BC3C344BQ34032403-70E9F200-02AC-4C93-9DDD-022619E575AFQ34141566-99C27396-EF7D-491D-9BF0-079625BC64ACQ34210726-ED214F62-F366-4ACF-AE8A-DF82099974FBQ34291232-38CD611F-FAF8-4207-BAC1-0A3176F73E9EQ34408525-D04010F5-2AB0-4F51-8065-BD853EFF8333Q34608635-4CB78E00-964F-4FB5-9A3B-843DC66C39ACQ34969789-A7040522-E37B-4387-BD24-B032A4161222Q34996098-191C4E05-4D51-4B49-A59B-88408CCBEC66Q35011895-3BE7B209-9358-4B5B-9E3A-EB3923AA433EQ35060329-F8A4C7FC-9527-4F6D-9287-FAEEAF0F945AQ35083639-6FC5355D-6E43-43BD-AECC-CE38A356E5A6Q35084786-F514ECB7-BF26-4209-A25B-88FFFC045E46Q35171200-991B000A-B7D6-4E87-941E-6D1DD36CB3EEQ35201899-2498D39C-C4D5-4DFB-B071-8044C924911CQ35232251-64924038-6AED-4B56-AAF9-ED38F2623A03Q35426181-E1DD722A-90A4-4A54-A7E8-EAD55932CEECQ35638851-07F835F7-E3ED-430D-9729-42EF4AAB91FD
P2860
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
@ast
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
@en
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
@nl
type
label
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
@ast
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
@en
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
@nl
prefLabel
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
@ast
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
@en
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
@nl
P2093
P356
P1476
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.
@en
P2093
A J Dannenberg
K Subbaramaiah
P304
P356
10.1677/ERC.0.0080097
P577
2001-06-01T00:00:00Z